Caricamento...
Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor
BACKGROUND: Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but have received little attention. The drugs, pembrolizumab and nivolumab are recently approved inhibitors of the PD-1 receptor that have overlapping AE profiles...
Salvato in:
| Pubblicato in: | Eur J Cancer |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998047/ https://ncbi.nlm.nih.gov/pubmed/27043866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2016.02.010 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|